



Kingdom of Saudi Arabia
Ministry of Higher Education
King Faisal University
College of Clinical Pharmacy



Name	Dr. Bandar E. Aldhubiab		
Specialization	Pharmaceutics		
Current Position	Dean		
Contact email (Official)	baldhubiab@kfu.edu.sa		
Alternate email	bander2727@yahoo.com	IP Phone	:03-5899787
Academic Qualifications	Degree/year/uni	Ph D Degree in Pharm. Sci, 2005-2010, College of Pharmacy, University of Arizona, USA	
	Degree/year/uni	B. Pharm. Sci., 2004, College of Pharmacy, King Saud University KSA	
Teaching Experience	➤ October 2010- present: Assistant professor, College of Clinical Pharmacy, King Faisal University. KSA		
	➤ February 2005- October 2005: Demonstrator (Teaching Assistant), College of Pharmacy, King Abdulaziz University, Kingdom of Saudi Arabia.		
Courses Taught and Teaching in KFU	➤ 2010111: Fundamentals of Pharmaceutics		
	➤ 2010223: Pharmaceutical Dosage Form		
	➤ 2030415: Clinical Pharmacokinetics		
	➤ 210314: Biopharmaceutics		
Research Interests	1. Increasing water solubility of drugs.		
	2. Formulation and development of targeted delivery.		
	3. Study of eutectic mixtures		
Research Grants Received	1. Development of transdermal delivery system of vildagliptin and its comparison with oral therapy, 2014, 82400 SAR		
	2. Formulation and Evaluation of Vildagliptin Dual Drug Release microsphere, 2014, 54900 SAR		
	3. Development of Nano based drug delivery system for the buccal delivery of acyclovir, 2014, 77400		
	4. Simultaneous determination of amlodipine, hydrochlorothiazide and several sartans by Liquid Chromatography and /or Capillary Electrophoresis in formulations and plasma, 2014 75400 SAR		



-
5. Formulation and evaluation of buccal films impregnated with selegiline loaded nanospheres, 2013, 68400SAR
 6. Preparation and Evaluation of Spraydried Oral Mucoadhesive Noveon Aa-1 Polycarbophil Nanoparticles Containing Anti-Diabetic Drug, 2013, 74400 SAR
 7. Development of a novel non invasive technique for therapeutic drug monitoring in epilepsy patients, 2013, 65900 SAR
 8. Development and validation of Stability indicating Chromatographic method for simultaneous determination of Statin and Gliptin , 2013, 57900SAR
 9. "Mucoadhesive microspheres containing a new antidiabetic drug: Preparation and in-vitro characterization" – 2012., SAR 87400
 10. "Validated Liquid Chromatographic method Development for Simultaneous estimation of Metformin and Gliptins". – 2012, SAR 63100
 11. "Self Emulsifying Drug Delivery Systems (SEDDS) for Oral Delivery of Lipophilic Anti-Muscarinic Drugs" - 2012, SAR 66,665/-
-
1. Kumria R, Anroop B, **AI-Dhubiab BE**. Loratidine buccal films for allergic rhinitis: development and evaluation. Drug Dev. Ind. Pharm. 40: 625-631, 2014.
 2. Anroop B, Singh K, **AI-Dhubiab BE**, Attimarad M, Harsha S, Alhaider IA, Skin uptake and clearance of ciclopirox following topical application, Biopharm. Drug Dispos. 34: 540-549, 2013.
 3. Anroop B, Jacob S, **AI-Dhubiab BE**, Attimarad MV, Harsha S, Basic considerations in the dermatokinetics of topical formulations, Brazilian J. Pharm. Sci. 49,423-434, 2013.
 4. **Bandar E AI-Dhubiab**. Formulation and in vitro evaluation of gelatin nanospheres for the oral delivery of selegiline. Curr. NanoSci. 2013, 9: 21-25. (2012 Impact factor 1.4).
 5. Anroop B Nair, Rachna Kumria, Sree Harsha S, Mahesh V Attimarad, **Bandar E AI-Dhubiab**, Ibrahim A Alhaider. In vitro techniques to evaluate buccal films. J Control Release. 2013, 166: 10-21. (2012 Impact factor 7.6).
 6. Sree Harsha, Mahesh V Attimarad, Tanveer A Khan, Anroop B Nair, **Bandar E. AI-Dhubiab**, Sighatullah Sangi and Arshia Shariff, Design and formulation of mucoadhesive microspheres of sitagliptin, J. Microencapsul. 2013, 30: 257-264. (2012 Impact factor 1.5).
 7. Anroop B Nair, Kishan Singh, Sree Harsha, **Bandar E AI-Dhubiab**, A comprehensive study to evaluate the effect of constant low voltage iontophoresis on transungual delivery, Drug Dev. Ind. Pharm. 2013, 39: 807-815. (2012 Impact factor 1.5).
 8. Satarupa Acharjee, Bijaya Ghosh, **Bandar E AI-Dhubiab**, Anroop B Nair, Understanding type 1 diabetes: etiology and models. Can. J. Diabetes, 37, 269-276, 2013. (2012 Impact factor 0.5).
 9. Anroop B Nair, Ashish Kaushik, Mahesh Attimarad, **Bandar E AI-Dhubiab**, Enhanced oral bioavailability of calcium using bovine serum albumin microspheres, Drug Deliv. 2012, 19: 277-85. (2012 Impact factor 2.0).
-

-
10. Mahesh V Attimarad, **Bandar E Al-Dhubiab**, Ibrahim A Alhaider, Anroop B Nair, Sree Harsha N, Mueen Ahmed K, Simultaneous determination of moxifloxacin and cefixime by first and ratio first derivative ultraviolet spectrophotometry, 2012, Chem. Cent. J. 2012, 6:105. (2012 Impact factor 1.3).
 11. Devendra Singh Chauhan, Sanjib Bhattacharya, **Bandar E Al-Dhubiab**, KK Mueen Ahmed, Comparative in vitro antioxidant evaluation of different extracts of *Camellia sinensis* leaves from different geographical locations, Pharmacog. Journal, 2012, 4, 44-46.
 12. **Bandar E Al-Dhubiab**, Pharmaceutical applications and phytochemical profile of *Cinnamomum burmannii*, Pharmacog. Rev., 2012, 6: 125 – 131.
 13. **Bandar E Al-Dhubiab**, Development and evaluation of fast dissolving tablets of glimepiride. Zagazig J. Pharm. Sci. 2011, 20, 1-5.
 14. **Bandar E. Al-Dhubiab**, Evaluation of olive oil ester-buffer system for the development of piroxicam micro-emulsion, Scientific Journal of King Faisal University (Basic and Applied Sciences) Vol.12 No.2 1432 (2011) 191-199.

Presentations and Abstracts

1. An LC-MS method for simultaneous determination of ofloxacin and cefixime in human plasma: Mass Spectrometry Applications in Clinical Laboratories, San Diego, CA, USA, 2013.
 2. Simultaneous determination of moxifloxacin and cefixime by first and ratio first derivative ultraviolet spectrophotometry. [American Association of Pharmaceutical Society, AAPS 2012]
 3. *In vitro* and *in vivo* evaluation of a novel carrier for calcium delivery [AAPS 2012]
 4. Therapeutic drug monitoring of carbamazepine by reverse iontophoresis [AAPS 2012]
 5. Skin permeation and dermatokinetics of ciclopirox olamine [AAPS 2012]
 6. Using NMP as a model for the solubility of the drugs [AAPS], 2009.
 7. Eutectic formation using PEG 400, [AAPS], 2009.
 8. Eutectic formation using disposable syringe method, [AAPS], 2009 Los Angeles CA.
 9. Effect of the pH on the solubilization of the drugs in the Micelle, [AAPS], 2008. Atlanta GA.
 10. Solubility of the sparingly soluble drugs using PVP, [AAPS], 2007. San Diego CA
 11. Synergic drug evaluation, [Armed Forces Hospital], 2004.
 12. Asthma & Counseling in asthmatic patient, [Armed Forces Hospital], 2004.
 13. 9th National Symposium in Dermatologic Surgery, 29-30 December 2004, Riyadh, Saudi Arabia.
 14. Recombinant Factor VIIa Symposium, November 2004, Jumeirah, UAE.
-

-
15. Barnd vs Generic Medications: Are they freely interchangeable? 29 May 2004, Saudi Pharmaceutical Society, Riyadh, Saudi Arabia.
 16. Reversing the Rising Incidence of Stroke, 26 March 2004, Riyadh, Saudi Arabia.
 17. What Do You Need to Know About Pharmacogenomics, 24 February 2003, Saudi Pharmaceutical Society, Riyadh, Saudi Arabia.
-

Memberships

- Saudi Pharmaceutical Society
 - American Association of Pharmaceutical Society (AAPS).
-

Workshops / Seminars attended

1. Malaysian Pharmaceutical Society- Pharmacy Scientific Conference, held during 21st – 23rd October 2011
 2. 46th ASHP Midyear Clinical meeting & exhibition at New Orleans Ernest N Morial Convention Center, New Orleans, Louisiana, USA
 3. ACS conference, San Diego, USA from 25th March to 29th 2012
 4. ASHP 2012, summer meeting and exhibition, Baltimore, MD on June 9th to 13th
 5. AAPS (The American Association of Pharmaceutical Scientist), Annual Meeting and Exposition was held from October 14th to 18th, 2012 in McCormick Place, Chicago.
-